Ah, retrospect investing!
Yes, it sure seems buying then is looking good now.
I would suggest that buying now also looks good, but for different reasons.
Investing assessment is always a dynamic and changing happening.
Back then, the lower share price represented the path of least resistance for mm amidst discouragement and minimal sellers, in all likelihood.
Recently the consistently rising share price, now up some 20+% from that low back then, seems to represent a whole new perspective of Ocata and the desire to start or add to one's position.
While, imo, the continuing rising price will be to benefit Lincoln's trading activity, the soon to be released increased dosaging Phase 2B cohort results, coupled with the much anticipated continuation of a much more extensive Phase 2, following the positive Phase 1 data.
Other matters like the possibility of accelerated EU possible acceptance and continuing positive 'new medical frontier medicine' media, not to mention the recent $12.00+ share price, all appear to be possibly signaling a turnaround, a stock going higher, in spite of much to still be proved and accomplished.
If $12.00+ a share recently was possible given the dynamics then, then given improved perceptions today, that sure seems like a reasonable objective to easily achieve that again?
Biotech often seem to be in a strange trading world all their own and often the best clue, the best indicator in judging a biotech and other equities in general, is very simply the action of the share price, which far too often tells tons before we retail shareholders will ever know what's going on.
